Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

Investors may be wary of AUROPHARMA as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 1.848000
forwardPE 15.665198
debtToEquity 22.248000
earningsGrowth 0.044000
revenueGrowth 0.063000
grossMargins 0.576220
operatingMargins 0.150730
trailingEps 58.930000
forwardEps 62.290000

AUROPHARMA's current ratio is 1.848, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as AUROPHARMA should not face any issues meeting its short-term liabilities with available resources.
Aurobindo Pharma Limited's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
AUROPHARMA's low Debt-to-Equity ratio shows that the company isn't heavily reliant on debt for financing. This implies a conservative approach to leveraging, reducing financial risk and demonstrating a solid financial foundation, which can enhance investor confidence in the company's long-term stability.
With a forward EPS greater than its trailing EPS, Aurobindo Pharma Limited is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

Over time, AUROPHARMA's price projections have been gradually lowered, signaling declining confidence in the company's future outlook. The downward revisions suggest analysts are becoming more cautious about AUROPHARMA's potential for growth.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


Analysts are favoring AUROPHARMA with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider AUROPHARMA as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.